Company: PFSA
Filing Date: 2025-05-13
Form Type: S-4/A
Source: 0001213900-25-042224
Chunk: 255

Company: Profusa, Inc.
Filing Date: 2025-05-13
Form: S-4/A
Chunk 255
---
 (other than Profusa). Of those twenty -sixpotential targets, NorthView engaged in more detailed due diligence and discussions directly with the senior executives and/or stockholders of nine such potential acquisition targets (the “Other Potential Targets”). The nine Other Potential Target businesses were comprised of: (i) a medical device company in wound care (“Company A”), (ii) a company with a novel thrombotic platform (“Company B”), (iii) a company in the electronic vehicle industry in India (“Company C”), (iv) a biotech company focused on patients non -responsiveto check point inhibitors (“Company D”), (v) a company in the global shipping and e -commerceindustry (“Company E”), (vi) a company in the non -surgicalspinal pain management business (“Company F”), (vii) a company in the business of producing a treatment for erectile dysfunction (“Company G”), (viii) and a company which conducts organ transplantation (“Company H”) and a company involved in esoteric diagnostics (“Company I”). As part of its acquisition strategy, NorthView generally did not pursue potential business combinations through widely competitive or auction processes, but instead focused on bilateral discussions with the key decision makers of each of the Other Potential Targets regarding a potential business combination. Both NorthView management and the NorthView Board reviewed a majority of the Other Potential Targets and analyzed the benefits of proceeding with a transaction with each of the Other Potential Targets reviewed. 123 As NorthView engaged in discussions with Company B, Company C, Company D, Company E, Company F, Company G, and Company H, NorthView decided not to proceed with each Other Potential Target for the following reasons: •Company B: We engaged in discussions around the overhang and potential dilution of NorthView’s public warrants, and potential valuation changes in the marketplace. On February10, 2022, NorthView’s Board approved issuing a non -exclusiveletter of intent to Company B. Company B did not sign and did not return the draft letter of intent which had been signed by NorthView. Additionally, Company B did not provide audited financial statements on a timely basis, which further solidified NorthView’s determination not to pursue an agreement with Company B. •Company C: Company C was introduced to NorthView by a prominent investment bank. Early discussions indicated that Company C needed to raise additional working capital in order to meet the estimated timetable to complete a business combination and terms regarding valuation were not able to be resolved. Additionally, PCAOB audited financials were not available